<DOC>
	<DOCNO>NCT01511913</DOCNO>
	<brief_summary>The purpose study examine safety Ipilimumab pattern use treatment unresectable metastatic melanoma post-approval setting .</brief_summary>
	<brief_title>A Multi-National , Prospective , Observational Study Patients With Unresectable Metastatic Melanoma</brief_title>
	<detailed_description>Time Perspective : study retrospective component involve subset patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Diagnosis unresectable metastatic melanoma Age 18 year old time entry study Patients initiate treatment unresectable metastatic melanoma medical practice ( e.g . communitybased , officebased , hospitalbased , academic setting ) within 21 day inform consent study OR case treatment yet initiate , documentation treatment strategy determine informed consent study , treatment must initiate within 28 day inform consent Ipilimumabtreated patient must receive treatment indication ( ) approve country residence receive treatment Current pending participation clinical trial examine therapy treatment cancer ( include unresectable metastatic melanoma ) Current use therapy treat primary cancer melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Unresectable metastatic cutaneous melanoma</keyword>
</DOC>